Related Experiment Video

Updated: Aug 14, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

Biologic therapies in clinical development for the treatment of rheumatoid arthritis

Mark C Genovese1

  • 1Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, 1000 Welch Road Ste. 203, Palo Alto, CA 94304, USA. Genovese@stanford.edu

Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases
|December 17, 2005
PubMed

Insights

New rheumatoid arthritis (RA) treatments are in development to improve disease remission. These novel agents target immune pathways, offering hope for better management beyond current therapies.

Area of Science:

  • Immunology
  • Rheumatology
  • Pharmacology

Background:

  • Current rheumatoid arthritis (RA) treatments face limitations in achieving disease remission for all patients.
  • An unmet need exists for therapies that offer improved efficacy and broader patient benefit.
  • Advancements in understanding RA's immune and inflammatory pathways reveal new therapeutic targets.

Purpose of the Study:

  • To review emerging therapeutic strategies for rheumatoid arthritis (RA).
  • To highlight novel agents targeting key immune and inflammatory pathways in RA.
  • To discuss the potential of these new treatments for improved disease management.

Main Methods:

  • Review of recent clinical trials and ongoing research in RA therapeutics.
  • Identification and categorization of novel agents based on their mechanisms of action.
  • Analysis of therapeutic targets including cytokines, immune cells, and signaling pathways.

Main Results:

  • Several novel agents targeting diverse pathways in RA are under investigation.
  • Promising results have emerged from recent clinical trials for some new therapies.
  • New treatment strategies aim to modulate proinflammatory cytokines, T and B cells, and signaling pathways.

Conclusions:

  • Novel therapeutic agents targeting specific molecular pathways show promise for rheumatoid arthritis (RA) treatment.
  • These emerging therapies may offer improved disease control and remission rates.
  • Continued research and development are crucial for advancing RA management and patient outcomes.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.